Dr. Andrew J. Armstrong, Duke University, USA

Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.

Dr. Paulo Lajes, Dr. Fernando Maluf and Dr. Andrey Soares, Brazil

Take Home Messages from ASCO GU 2019 (Portuguese)

Dr.  Karine Trindade, Oncocentro, Brazil 

Dr. Fernando Nunes, Clinica Clion, Brazil

Highlights in First Line RCC  (Portuguese)

Dr. Ana Paula Cardoso, Hospital Israelita Albert Einstein, Brazil

Updates in Urothelial tumors from ASCO GU 2019 (Portuguese​)

×

Dr. Brian Rini, Cleveland Clinic, USA

Keynote 426 - expert opinion 

Dr. Sumanta K. Pal, City of Hope, USA

Highlights in RCC

Dr.  Fabio Shutz, BP Hospital, Brazil

Highlights in RCC - Keynote 426 (Portuguese)

Dr. Toni Choueiri, Dana-Farber Cancer Institute, USA

Highlights in RCC from ASCO GU 2019

Dr. Manuel Maia, COP, Brazil

Updates in Prostate Cancer from ASCO GU2019

Dr. Orazio Caffo, Santa Chiara Hospital, Italy

A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.

ASCO GU 2019 - Dr. Enrique Grande, MD Anderson, Spain

Clinical research is cost effective in patients with advanced kidney cancer.​

Dr.  Fabio Shutz, BP Hospital, Brazil 

Take Home Messages in RCC from ASCO GU 2019 (Portuguese)

Dr. Ana Paula Cardoso, Hospital Israelita Albert Einstein, Brazil

Highlights de in RCC (Portuguese)

Dr. Guru Sonpavde, Dana-Farber Cancer Institute, USA

Highlights in Bladder Cancer